Ensysce Hires Kirkpatrick as President, CEO

Cancer treatment research firm Ensysce Biosciences Inc. reported Monday that Dr. D. Lynn Kirkpatrick has come aboard as president and chief executive officer. Houston-based Ensysce, which is studying the use of fullerene carbon nanotubes for therapeutic cancer applications, said Kirkpatrick has previously brought three agents to market. As the co-founder of Pro1X Pharmaceuticals, Kirkpatrick served as CEO from 1999 until its acquisition by Biomira Inc. in 2006. For the next two years, Ensysce noted, Kirkpatrick was chief science officer of the merged company, which changed its name to Oncothyreon Inc. in 2007. Ensysce is a privately held firm founded in 2008 with intellectual property developed at Rice University.